Menveo – GSK
Indication and Usage –
- MENVEO is indicated for active immunization of children (from 2 years of age), adolescents and adults to prevent invasive meningococcal disease caused by Neisseria Meningitidis groups A, C, W-135 and Y.
- The use of this vaccine should be in accordance with official recommendations.
Dosage and Administration –
- MENVEO is given as an intramuscular injection, preferably into the deltoid muscle.
- It must not be administered intravascularly, subcutaneously or intradermally.
- Menveo is administered in single dose above 2 years of age.
Contraindications –
- Hypersensitivity to the active substance or to any of the excipients listed in Section 6.1 List of Excipients, or diphtheria toxoid (CRM197), or a life-threatening reaction after previous administration of a vaccine containing similar components.
- As with other vaccines, MENVEO should be postponed in individuals suffering from an acute severe febrile illness. The presence of a minor infection is not a contraindication.
Adverse reactions –
- Very common: irritability, malaise, injection site pain, injection site erythema (≤50 mm), injection site induration. Injection site pruritus.
- Some adverse reactions are sleepiness, headache, nausea, vomiting, diarrhea, rash, myalgia and arthralgia.
Drug interactions and other interactions –
- MENVEO can be given concomitantly with any of the following vaccines: monovalent and combined hepatitis A and B, yellow fever, typhoid fever (Vi polysaccharide), Japanese encephalitis and rabies.
- In adolescents (11 to 18 years of age), MENVEO has been evaluated in two co-administration studies with either Tetanus, Reduced Diphtheria and Acellular Pertussis Vaccine, Adsorbed (Tdap) alone or Tdap and Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant (HPV), both of which support the co-administration of the vaccines.
- Antibody responses to MENVEO and the diphtheria, tetanus or HPV vaccine components were not negatively affected by co-administration.
After vaccination, over 97% of subjects had detectable pertussis titers to all three pertussis antigens.
